All Pfizer published press releases by date and/or category of news
06.23.2022 Financial Investments Vaccines Valneva and Pfizer Announce Closing of Equity Investment 06.23.2022 Financial Finance Pfizer Declares Third-Quarter 2022 Dividend 06.20.2022 Vaccines Vaccines Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 06.17.2022 Vaccines COVID-19 Vaccines Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age 06.17.2022 Research and Pipeline Research Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain 06.14.2022 Prescription Medicines Medicines Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA 06.09.2022 Financial Investments Pfizer Completes Acquisition of ReViral 06.09.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 06.08.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 06.06.2022 Financial COVID-19 Investments Vaccines Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. 06.04.2022 Prescription Medicines Medicines Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer 06.02.2022 Medicines Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.